Abstract：ObjectiveTo investigate the clinical effect of immunosuppressant Cyclophosphamide in the treatment of acute interstitial nephritis.Methods30 patients with acute interstitial nephritis who were admitted to our hospital from June 2015 to April 2017 were enrolled as the study subjects.According to the different treatment methods,the patients were divided into the control group and the treatment group,with 15 cases in each group.Patients in the control group were given hormones,and patients in the treatment group were given hormones combined with cyclophosphamide immunosuppressant.Improvement of relevant biochemical indicators(including serum uric acid,blood urea nitrogen,serum creatinine,endogenous creatinine clearance rate),the length of hospital stay,the incidence rate of adverse reactions,the total effective rate of treatment were compared between the two groups.ResultsThere were no significant differences in the relevant biochemical indicators of serum uric acid,blood urea nitrogen,serum creatinine,endogenous creatinine clearance rate between the two groups before treatment(P＞0.05).The level of serum uric acid,blood urea nitrogen,serum creatinine in the treatment group after treatment were significantly lower than those in the control group,the level of serum creatinine clearance rate in the treatment group after treatment was significantly higher than the control group,with significant difference (P＜0.05).The length of hospital stay in the treatment group was significantly shorter than that in the control group,with significant difference (P＜0.05).The incidence rate of adverse reactions in the treatment group was 6.7%,which was significantly less than 13.3%in the control group,with significant difference (P＜0.05).Conclusion The application of Cyclophosphamide immunosuppressant in the treatment of patients with acute interstitial nephritis can effectively improve the biochemical indicators of patients,so as to rapidly promote the recovery of renal function in patients,and the efficacy is safe and reliable.
Ehinger KH，Hansson MJ，Sjvall F，et al.Bioequivalence and tolera-bility assessment of a novel intravenous ciclosporin lipid emulsion compared to branded ciclosporin in Cremophor E[J].Clin Drug Investig，2013，33（1）：25-34．
[5]
Sprunger DB，Olson AL，Huie TJ，et al.Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease[J]. Eur Respir J，2012，39（1）：125-132.
京公网安备 11010502046607号